{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:54:00Z","timestamp":1770144840788,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,27]]},"DOI":"10.7759\/cureus.79734","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T08:45:02Z","timestamp":1740645902000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-Life Experience of HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Advanced Breast Cancer Patients Treated With T-DXd (Trastuzumab Deruxtecan): A Multicentric Portuguese Study"],"prefix":"10.7759","author":[{"given":"Rita","family":"Bizarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Pazos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarida","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f3nia","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Duarte Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Eiriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Leit\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Bento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"In\u00e1cio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Alpoim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Correia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Branco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Passos-Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mafalda","family":"Casa-Nova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Alberto","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023, 73:17-48. 10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad308","article-title":"Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study","volume":"29","author":"Botticelli A","year":"2024","unstructured":"Botticelli A, Caputo R, Scagnoli S, et al.. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study. Oncologist. 2024, 29:303-10. 10.1093\/oncolo\/oyad308","journal-title":"Oncologist"},{"key":"ref3","unstructured":"HER2 in breast cancer. ESMO biomarker factsheet. (2015). Accessed: November 19, 2024: https:\/\/oncologypro.esmo.org\/education-library\/factsheets-on-biomarkers\/her2-in-breast-cancer."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2009.825","article-title":"Breast cancer subtypes based on ER\/PR and Her2 expression: comparison of clinicopathologic features and survival","volume":"7","author":"Onitilo AA","year":"2009","unstructured":"Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER\/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009, 7:4-13. 10.3121\/cmr.2009.825","journal-title":"Clin Med Res"},{"key":"ref5","article-title":"Overview of the CLEOPATRA trial: implications for advanced practitioners","volume":"7","author":"Herold K","year":"2016","unstructured":"Herold K. Overview of the CLEOPATRA trial: implications for advanced practitioners. J Adv Pract Oncol. 2016, 7:83-9.","journal-title":"J Adv Pract Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.557","article-title":"Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression","volume":"22","author":"Tripathy D","year":"2004","unstructured":"Tripathy D, Slamon DJ, Cobleigh M, et al.. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004, 22:1063-70. 10.1200\/JCO.2004.06.557","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000055400","article-title":"First-line Herceptin monotherapy in metastatic breast cancer","volume":"61","author":"Vogel CL","year":"2001","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, et al.. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001, 61:37-42. 10.1159\/000055400","journal-title":"Oncology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27603","article-title":"Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting","volume":"11","author":"Prete SD","year":"2020","unstructured":"Prete SD, Montella L, Arpino G, et al.. Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. Oncotarget. 2020, 11:2083-91. 10.18632\/oncotarget.27603","journal-title":"Oncotarget"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102468","article-title":"T-DM1 after pertuzumab plus trastuzumab: treatment sequence-induced selection bias in HER2-positive metastatic breast cancer","volume":"14","author":"Sanglier T","year":"2022","unstructured":"Sanglier T, Fabi A, Flores C, Flahavan EM, Pena-Murillo C, Meyer AM, Montemurro F. T-DM1 after pertuzumab plus trastuzumab: treatment sequence-induced selection bias in HER2-positive metastatic breast cancer. Cancers (Basel). 2022, 14:2468. 10.3390\/cancers14102468","journal-title":"Cancers (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi S","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, et al.. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020, 382:610-21. 10.1056\/NEJMoa1914510","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103699","article-title":"Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial","volume":"9","author":"Vaz Batista M","year":"2024","unstructured":"Vaz Batista M, P\u00e9rez-Garc\u00eda JM, Cortez P, et al.. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial. ESMO Open. 2024, 9:103699. 10.1016\/j.esmoop.2024.103699","journal-title":"ESMO Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi S","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al.. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022, 387:9-20. 10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9 F","year":"2023","unstructured":"Andr\u00e9 F, Park YH, Kim SB, et al.. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023, 401:1773-1785. 10.1016\/S0140-6736(23)00725-0","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s J","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, et al.. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022, 386:1143-54. 10.1056\/NEJMoa2115022","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184522","article-title":"Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies","volume":"15","author":"Tapia M","year":"2023","unstructured":"Tapia M, Hernando C, Mart\u00ednez MT, et al.. Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies. Cancers (Basel). 2023, 15:4522. 10.3390\/cancers15184522","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update","volume":"41","author":"Wolff AC","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al.. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update. J Clin Oncol. 2023, 41:3867-72. 10.1200\/JCO.22.02864","journal-title":"J Clin Oncol"},{"key":"ref17","unstructured":"Common terminology criteria for adverse events (CTCAE). (2017). Accessed. November 20, 2024: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.09.069","article-title":"Design of clinical trials for therapeutic cancer vaccines development","volume":"625","author":"Mackiewicz J","year":"2009","unstructured":"Mackiewicz J, Mackiewicz A. Design of clinical trials for therapeutic cancer vaccines development. Eur J Pharmacol. 2009, 625:84-9. 10.1016\/j.ejphar.2009.09.069","journal-title":"Eur J Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura C","year":"2024","unstructured":"Saura C, Modi S, Krop I, et al.. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2024, 35:302-7. 10.1016\/j.annonc.2023.12.001","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-world evidence in oncology: opportunities and limitations","volume":"25","author":"Di Maio M","year":"2020","unstructured":"Di Maio M, Perrone F, Conte P. Real-world evidence in oncology: opportunities and limitations. Oncologist. 2020, 25:e746-52. 10.1634\/theoncologist.2019-0647","journal-title":"Oncologist"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio M","year":"2015","unstructured":"Di Maio M, Gallo C, Leighl NB, et al.. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015, 33:910-5. 10.1200\/JCO.2014.57.9334","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/336971-real-life-experience-of-her2-human-epidermal-growth-factor-receptor-2-positive-advanced-breast-cancer-patients-treated-with-t-dxd-trastuzumab-deruxtecan-a-multicentric-portuguese-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T08:45:07Z","timestamp":1740645907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/336971-real-life-experience-of-her2-human-epidermal-growth-factor-receptor-2-positive-advanced-breast-cancer-patients-treated-with-t-dxd-trastuzumab-deruxtecan-a-multicentric-portuguese-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.79734","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}